US kidney care speciailst Evergreen Nephrology announced on Tuesday the appointment of David Young to its board of directors.
Young has served in leadership roles such as CEO of GenesisCare, president & CEO of Physicians Endoscopy Inc and COO of Privia Health Inc. He has also worked in senior-level positions at Smile Brands Inc McKesson Specialty Health and US Oncology Inc.
Young will continue to serve on the boards of GenesisCare Cayman Holdings, GenesisCare UK Ltd and Biocartis Holdings Inc.
Adam Boehler, Evergreen Nephrology executive chairman, said: "Evergreen is at an exciting point in its growth, forming new partnerships with nephrologists nationwide, aligning with new payors, and pioneering cutting-edge research. David's extensive operational, financial and executive leadership in healthcare will be invaluable as we pursue our work of providing exceptional kidney care tailored to each patient's journey."
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis